Overview

Over 98% of all drugs struggle to cross the Blood-Brain Barrier (BBB), hindering their usability against CNS diseases. D2B3’s breakthrough is a patented human monoclonal antibody (Mab), that transiently and highly specifically opens the BBB, achieving high drug penetration to the brain.

The lead asset D2B3-01 has shown exceptional performance in in vivo proof of concept studies delivering a variety of drug classes (small molecules to biologics) across the BBB and unlocking therapeutic efficacy in different rodent CNS-disease models. Initially, D2B3 hopes to extend the reach of generic – off-patent – therapeutic assets to the brain, promising lower regulatory burdens and fast clinical progression, bringing hope to patients living with CNS-diseases. In the future D2B3 hopes to expand out additional pipelines enabling novel assets through in-licensing and in house pipeline development as well as shared drug pipelines through partnerships with Pharma-companies – many of which have signaled interest.